| 09:30 - 09:45 |
BC-LRAT
(5 mins) |
Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC) |
Dr. Amit Sharma (MO)
(Presenter) |
BC-LRAT
(5 mins) |
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level metaanalysis of 14,993 pre-menopausal women in 25 randomized trials |
Dr. Chandrashekhar Prasad Singh (MO)
(Presenter) |
BC-LRAT
(7 mins) |
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer. |
Dr. Adithya Krishna S (MO)
(Presenter) |
| Moderator: Dr. Sachin Trivedi (MO) |
Panelists |
| 09:45 - 10:05 |
PD
(30 mins) |
Panel Discussion on Track: BC-LRAT - Breast Cancer - Local Regional Adjuvant Track |
Dr. Mahesh Bandimegal (SO)
Dr. Suraj Manjunath (SO)
Dr. Sanjib Kumar Mishra (RO)
Dr. Susanta Kumar Paikaray (MO)
Dr. K.B. Linge Gowda (PM)
Dr. Premitha R (RO) |
| Moderator: Dr. Sachin Trivedi (MO) |
Panelists |
| 10:05 - 10:35 |
IS(Roche)
(20 mins) |
Panel Discussion on Track: BC-LRAT - Breast Cancer - Local Regional Adjuvant Track |
Dr. Vishwanath S
(Speaker)
Dr. Shweta S Ninutha
Dr. Sreevalli A
Dr. Sangeetha P. (Panelists) |
| 10:55 – 11:15 |
(20 mins) |
Tea Break |
| Session 02 | Track: BC-M - Breast Cancer - Metastatic |
| Chairpersons: Dr. Belliappa M.S (RO), Dr. Vijay D. G (SO) |
| 10:55 - 11:15 |
BC-M
(5 mins) |
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). |
Dr. Sashanka Shekhar Das (MO)
(Presenter) |
BC-M
(5 mins) |
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. |
Dr. Spoorthi G (MO)
(Presenter) |
BC-M
(5 mins) |
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). |
Dr. Balaji J (MO)
(Presenter) |
BC-M (Py-On)
(5 mins) |
Phase 3 randomized placebo-controlled trial of donepezil for late cancer-related cognitive impairment in breast cancer survivors exposed to chemotherapy from the Wake Forest NCORP Research Base REMEMBER trial (WF97116). |
Ms. Rhea Daruwala (PYO)
(Presenter) |
| 11:15 - 11:35 |
IS (Lilly)
(20 mins) |
Industry Session: Discover the impact of Latest monarchE (5-year) data on clinical approach for HR+ HER2- Node positive High Risk Early breast cancer |
Dr. Ravi T (MO)
(Speaker) |
| 11:35 - 11:55 |
IS (Novartis)
(20 mins) |
Dillema of choosing a CDK 4/6 I in 1st Line MBC setting- Reality or Myth |
Dr. Satheesh C T
(Speaker) |
| Moderator: Dr. Sachin Trivedi (MO) |
Panelists |
| 11:55 - 12:25 |
PD
(30 mins) |
Panel Discussion on Track: BC-M - Breast Cancer - Metastatic |
Dr. Lohith Reddy (RO)
Dr. Cathlyn Niranjana Bennett (PYO)
Dr. Poonam Patil (MO)
Dr. Shilpa Kandipalli (MO)
Dr. Krithika Murugan (SO)
Dr. Vijayashree Murthy (SO)
Dr. Sai Vivek Velukuru (MO)
Dr. Hamsini R S (RO) |
| 12:45 - 13:25 |
40 Mins |
Lunch and Poster Session |
| 40 Mins |
Poster Session Chairpersons: Dr. K.S. Gopinatd (SO), Dr. Suresh Advani (MO), Dr. Mithua Ghosh (Gene), Dr. Brindha Sitaram (PYO), Dr. Vinod K Ramani (MO), Dr. Prabhu Nesargikar (SO), Dr. M. S. Belliappa (RO), Dr. Govind Babu (MO) |
Poster Presenters |
40 Mins
(15 Posters) |
P1: BC-LRAT |
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. |
Dr. Muthulingesh (Apollo) |
| P2: BC-M |
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer. |
Dr. Pradnya Modak (Apollo) |
| P3: BC-M |
CDK4/6 Inhibitors: New Populations, Different Settings |
Dr. Varsha (Apollo) |
| P4: CNST |
Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). |
Dr. Ratanchandani Krishna Khushiram (Aster) |
| P5: CNST |
BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis. |
Dr. Mankada Sakina Hakimuddin (Aster) |
| P6: CNST |
Vaccines, Checkpoints, and Electrical Fields: Immunotherapy and Glioblastoma Multiforme |
Dr. Manasee Arun Rajadhyaksha (Sri Shankara) |
| P7: CNST |
Association of CDK4 amplification with duration of response to bevacizumab in glioblastoma. |
Dr. Dr Praveen Kumar D V M (Sri Shankara) |
| P8: DT-I |
The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures. |
Dr. Thapashwi B G (Sri Shankara) |
| P9: DT-I |
Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001TGF-ß Trap. |
Dr. Riya Saboo (Sri Shankara) |
| P10: DT-MTGTB |
"Cycling" Toward the FUTURE in Breast Cancer and Beyond |
Dr. Prabhat Ranjan (SRIHER) |
| P11: DT-MTGTB |
Damage Control: Emerging Therapies for the DDR Pathway |
Presenter |
| P12: DT-MTGTB |
A phase II study of tinostamustine in patients (pts) with advanced solid tumours. |
Presenter |
| P13: GC-C/A |
Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study. |
Dr. Baghath singh (MMC) |
| P14: GC-C/A |
Systemic Therapies for Advanced Colorectal Cancer: The Past, Present and Future |
Dr. Karthik (MMC) |
| P15: GC-GPH |
Treating Gastroesophageal Cancer: New Lights on the Horizon |
Presenter |
| Inaugural Ceremony |
Speakers |
| 13:25 - 13:30 |
INC
(110 Mins) |
Welcome address |
Dr. Radheshyam Naik (MO) |
| 13:30 - 13:35 |
Scientific Program - What to expect? |
Dr. Govind Babu (MO) |
| 13:35 - 14:15 |
Plenary Talk - Streaming Data and Genomics Driven Therapies in Patient Management |
Dr. B.S. Ajaikumar (RO & MO)
Executive Chairman, HCG Hospitals |
| 14:15 - 14:45 |
Keynote Address - Breast cancer treatments and how to build a system that can deliver cancer research at pace in high volume and remain sustainable |
Dr. Andrew Wardley (MO) |
| 14:45 - 14:55 |
Topic TBD |
Dr. Ganesh Nayak (CS) |
| 14:55 - 15:10 |
Address by Chief Guest |
Dr. M K Ramesh
Vice-Chancellor, Rajiv Gandhi University of Health Sciences |
| 15:00 - 15:20 |
Tea Break |
| Session 03 || Tracks: (i) CNST - Central Nervous System Tumors || (ii) HNC - Head and Neck Cancer |
| Chairperson: Dr. Indoor Ammbulkar (MO), Dr. Vishal Rao U.S (SO), Dr. Prakash Shetty |
| 15:30 - 15:55 |
CNST
(5 Mins) |
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. |
Dr. Swaratika Mazumdar (MO) NH
(Presenter) |
HNC
(5 Mins) |
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. |
Dr. Sathish Sharma (MO)
(Presenter) |
HNC
(5 Mins) |
Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial. |
Dr. Kshitij Rajesh Domadia (MO)
(Presenter) |
HNC
(5 Mins) |
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. |
Dr. Shalini Thakur (SO)
(Presenter) |
HNC (Py-On)
(5 Mins) |
A multi-component educational intervention for oncologists to improve tobacco cessation treatment among patients with cancer who smoke. |
Ms. Neha Tojan (PYO)
(Presenter) |
| 15:45 - 16:05 |
IS
(20 Mins) |
Industry Session |
Speaker (TBC) |
| Moderator: Dr. Linu Jacob (MO), Dr. Ramesh S Bilimagga (RO) |
Panelists |
| 15:55 - 16:25 |
PD
(30 Mins) |
Panel Discussion on Tracks: (i) CNST - Central Nervous System Tumors | (ii) HNC - Head and Neck Cancer |
Dr. Kumaraswamy (RO)
Dr. Sudhir Nair (SO)
Dr. Richa Vaish (SO)
Dr. Poonam Joshi (SO)
Dr. Mahati Chittam (PYO)
Dr. Gaurav Medikeri (SO)
Dr. Srinivas K.G
Dr Vijeta J (RO)
Dr. Krishnappa Ramachandrappa (SO)
Dr. Prakash Shetty (SO) |
| Session 04 | Tracks: (i) DT-I - Developmental Therapeutics - Immunotherapy | (ii) DT-MTGTB - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology |
| Chairperson: Dr. Govind babu (MO) | Dr. Lakshmaiah K C (MO) |
| 16:25 - 16:50 |
DT-I
(5 Mins) |
Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609). |
Dr. Vishwajeeth Pai |
DT-I
(5 Mins) |
Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes. |
Dr. Mohammed Naseer R
(Presenter) |
DT-I
(5 Mins) |
First-line treatment of fecal microbiota transplantation for immune-mediated colitis. |
Dr. Mangesh P Kamath (MO)
(Presenter) |
DT-MTGTB
(5 Mins) |
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. |
Dr. Srikanth Dikkala (MO)
(Presenter) |
DT-MTGTB
(5 Mins) |
Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study. |
Dr. LaguduPerraju Bhaskar Bhuvan (MO)
(Presenter) |
| 16:50 - 17:05 |
(15 Mins) |
Predictive factors in Immunotherapy |
Dr. Radheshyam Naik (MO)
(Speaker) |
| 17:05 - 17:20 |
IS
(15 Mins) |
Role of Immunotherapy marker in developmental therapeutics |
Dr. VIjay Agarwal (MO)
(Speaker) |
| 17:20 - 17:35 |
IS
(15 Mins) |
Role of Tumor microenvironment in cancer therapy responses |
Dr. Sowmya Uthiah
(Speaker) |
| 17:35 - 17:50 |
IS
(15 Mins) |
Industry Session by MSD: KN048, role of Immunotherapy in 1st line uR or m HNSCC |
Dr. Aditya Murali
(Speaker) |
| Moderators: Dr. Govind Babu (MO) |
Panelists |
| 18:00 - 18:30 |
PD
(30 Mins) |
Panel Discussion on Tracks: (i) DT-I - Developmental Therapeutics - Immunotherapy | (ii) DT-MTGTB - Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology |
Dr. Amit Rauthan (MO)
Dr. Smita Sardana
Dr. Abhay K Kattepur (SO)
Dr. Chandrashekhara S H (RO)
Dr. Vijayaraj S Patil (SO) |